Previously treated high-risk chronic lymphocytic leukemia patients saw a significantly better overall response rate when adding TG Therapeutics Inc.'s glycoengineered anti-CD20 candidate, TG-1101 (ublituximab), to Imbruvica (ibrutinib) during a phase III study called Genuine.